Ticker LaunchUplisting · OSTX
OS Therapies Inc
OS Therapies Inc (OSTX), already reporting to the SEC, moved up to NYSE American on Aug 1, 2024 with an offering at $4.00 per share raising $6.4M. Brookline was lead-left underwriter, joined by Arcadia. Olshan Frome Wolosky advised the company and Sichenzia Ross Ference Carmel advised the underwriters.
OS Therapies Incorporated is a clinical-stage biopharmaceutical company developing treatments for osteosarcoma and other solid tumors, with a mission of addressing bone cancers in children and young adults. Its lead core product candidate is OST-HER2.
- Status
- Uplisting
- Ticker
- OSTX
- Exchange
- NYSE American
- Listed
- Aug 1, 2024
- Price
- $4.00
- Raised
- $6.4M
- Market cap at IPO price
- $80.2M
- First filed
- Mar 31, 2023
- Company counsel
- Olshan Frome Wolosky
- Underwriters' counsel
- Sichenzia Ross Ference Carmel
- Sector
- Biotech & pharma
- Country / state
- MD
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Mar 31, 2023
- Latest amendment Jun 13, 2024
- Final prospectus (424B4) Aug 1, 2024
- All filings on EDGAR CIK 1795091
Other Biotech & pharma uplistings in 2024
- Alpha Cognition Inc.ACOG · Nov 13, 2024
- Synergy CHC Corp.SNYR · Oct 23, 2024 · $10.3M
- Impact Biomedical Inc.IBO · Sep 17, 2024 · $4.5M